Physician

Balaji Srinivasan, MD

According to 2025 Medicare claims, Balaji Srinivasan, MD (NPI: 1467456244) practices nephrology in the La Crosse-Onalaska, WI-MN market, with the plurality of this provider's patient population coming from La Crosse, WI. This provider's primary affiliated billing organization is GUNDERSEN LUTHERAN MEDICAL CENTER INC (NPI: 1376593442; TIN: 390813416) and primary practice location at 54650-8677. Srinivasan is affiliated with the Gundersen ACO (ACO ID: A5094), participating under the MSSP model.

Srinivasan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 296 traditional Medicare patients, billed 1,615 HCPCS/CPT codes, and received $150,829 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 3,316 prescription claims across 413 beneficiaries totaling $206,388 in drug costs, led by Xifaxan (Rifaximin). DME data shows 54 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have declined steadily, from $275,873 to $206,388. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	446	2,875	$180,844
2016	432	2,749	$159,381
2017	443	2,008	$185,670
2018	416	2,003	$134,233
2019	383	2,170	$138,918
2020	387	1,759	$143,410
2021	403	1,891	$161,193
2022	365	1,435	$134,822
2023	344	1,431	$127,553
2024	296	1,615	$150,829

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	336	4,085	$275,873
2016	309	3,755	$271,275
2017	336	3,917	$334,854
2018	329	3,415	$241,463
2019	320	2,991	$191,636
2020	310	2,697	$184,026
2021	326	2,617	$167,759
2022	337	2,295	$156,082
2023	391	2,864	$206,864
2024	413	3,316	$206,388

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	12	$585
2017	N/R	13	$1,170
2018	N/R	70	$4,755
2019	N/R	37	$4,511
2020	N/R	85	$1,484
2021	N/R	76	$1,697
2022	N/R	61	$1,589
2023	N/R	49	$1,392
2024	N/R	54	$1,448

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	39	247	$272
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	38	133	$223
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	121	171	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	116	146	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	203	296	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xifaxan	Rifaximin	14	357	$35,042
Farxiga	Dapagliflozin Propanediol	17	924	$16,572
Bumetanide	Bumetanide	217	12,814	$15,093
Renvela	Sevelamer Carbonate	15	358	$12,430
Clinolipid	Fat Emulsion/Olive/Soy/Phospho	52	358	$12,361

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7500	Azathioprine, oral, 50 mg	N	N/R	13	$1,006
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$150
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	13	$9

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Balaji Srinivasan, MD?

Tedicare shows public-source Medicare data for Balaji Srinivasan, MD (NPI 1467456244), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Balaji Srinivasan, MD have ACO affiliation data?

Balaji Srinivasan, MD is shown with ACO affiliation data for Gundersen ACO (MSSP, ACO ID A5094).

What billing organization is linked to Balaji Srinivasan, MD?

Balaji Srinivasan, MD is linked to GUNDERSEN LUTHERAN MEDICAL CENTER INC (billing NPI 1376593442) in the available physician profile data.

Does Balaji Srinivasan, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.